Please login to the form below

Not currently logged in
Email:
Password:

Immodulon Therapeutics appointments two new board of directors

Anthony Bolton and Sir Simon Robertson join the biopharma firm

Sir Simon RobertsonImmodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology has made two new senior appointments to its board of directors.

Anthony Bolton, one of the UK's most successful investment fund managers and Sir Simon Robertson (pictured), deputy chairman of HSBC, will join Immodulon as non-executive directors with immediate effect.

Bolton joined Fidelity in 1979. He has managed several Fidelity funds including the Fidelity Special Situations that he ran for 28 years up to 2007. During this time the fund became the largest unit trust in the UK and achieved annual growth of almost 20%. 

More recently, he wrote an investment book 'Investing Against the Tide' and managed Fidelity China Special Situations PLC whilst based in Hong Kong for four years.

Although he retired from fund management in 2014 he remains a board member and adviser at Fidelity as well as a trustee of its charitable foundations.

Sir Simon joined the board of HSBC in 2006 and has served on a number of board committees. 

He has an extensive background in international corporate advisory work and a wealth of experience in mergers and acquisitions and financial markets. 

His international experience includes working in France, Germany, the UK and the US. He was knighted in the 2010 Queen's birthday honours list in recognition of his services to business.

16th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan...

Infographics